Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 36%
Hold 36%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is a healthcare company that operates in the MedSurg, Dental Solutions, and Health Information Systems segments, with a strong focus on innovation and technology. The company has a solid financial foundation, with increasing EPS and revenue estimates, and is making strategic moves such as divesting non-core areas and implementing M&A to drive future growth. Despite some quarterly noise stemming from its spinoff from 3M, Solventum is on track to meet its long-term financial targets, making it an attractive investment opportunity.

Bears say

Solventum is expected to struggle in the near future with declining OMs, a challenging ERP cutover in the US and Canada, and the impact of tariffs on their bottom line, which could potentially be offset by contributions from their recent Acera acquisition. Furthermore, their unchanged guidance for low organic growth and lack of reassurance regarding potential refunds for tariffs suggest that their financial performance may continue to be underwhelming. These factors, along with the likelihood of continued pressure on earnings and margins from external factors, suggest a negative outlook on Solventum's stock.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Hold based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Hold consensus rating as of Jul 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.